5th Edition of International Heart Congress
June 24-26, 2027 | Hybrid Event
Valvular Atrial Fibrillation
Valvular Atrial Fibrillation (VAF) is a specific subtype of atrial fibrillation characterized by the presence of significant heart valve disease. In individuals with VAF, irregular and often rapid heartbeats occur due to abnormal electrical signals in the atria, the upper chambers of the heart. The presence of valvular heart disease, such as mitral stenosis or a mechanical heart valve, increases the risk of developing VAF. Managing VAF poses unique challenges, as treatment strategies need to consider both the atrial fibrillation and the underlying valvular pathology. Healthcare professionals typically tailor their approach based on factors like the severity of the valve disease, overall health status, and individual patient considerations. Close monitoring and a collaborative, multidisciplinary approach are essential in addressing the complexities of Valvular Atrial Fibrillation.
John R Doty
Intermountain Medical Center, United States
Agustin Joison
Cordoba Catholic University, Argentina
Thomas J Webster
Brown University, United States
Uwe Peter Tigor
Auxilius Pharma, United States
Sergey Suchkov
N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Bijoy Krishna Banik
National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, IndiaSubmit your abstract Today
Title : Healing a broken heart: One nano beat at a time
Thomas J Webster, Brown University, United States
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Antidiabetic agents – From treating diabetes to providing positive cardiovascular outcome
Syed Raza, Awali Hospital, Bahrain